Factor VIII inhibitors development following introduction of B-domain-deleted recombinant factor VIII in four hemophilia A previously treated patients

Journal of Thrombosis and Haemostasis

Volumn 1, Issue 11, 2003, Pages 2450-2451

  Roussel Robert, V ^a   Torchet, M F ^b   Legrand, F ^b   Rothschild, C ^b   Stieltjes, N ^a  

^a Cochin Hospital ^*  (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIBODY; B DOMAIN DELETED FACTOR VIII; B-DOMAIN-DELETED FACTOR VIII; BLOOD CLOTTING FACTOR 8; PEPTIDE FRAGMENT;

ADULT; AGED; ANTIBODY PRODUCTION; BLOOD; HEMOPHILIA A; HUMAN; IMMUNOLOGY; LETTER; MIDDLE AGED;

ADULT; AGED; ANTIBODY FORMATION; FACTOR VIII; HEMOPHILIA A; HUMANS; ISOANTIBODIES; MIDDLE AGED; PEPTIDE FRAGMENTS;

EID: 3543110117     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1046/j.1538-7836.2003.0468a.x     Document Type: Letter

References (9)

1. McMillan CW, Shapiro SS, Whitehurst D, Hoyer LW, Rao AV, Lazerson J. The natural history of factor VIII:C inhibitors in patients with hemophilia A: a national cooperative study. II. Observations on the initial development of factor VIII:C Inhibitors. Blood 1988; 71: 344-8.
2. Rosendaal FR, Nieuwenhuis HK, van den Berg HM, Heijboer H, Mauser-Bunschoten EP, van der Meer J, Smit C, Strengers PFW, Briet E, the Dutch Hemophilia Study Group. A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in the Netherlands. Blood 1993; 81: 2180-6.
3. Peerlinck K, Arnout J, Gilles JG, Saint-Remy JM, Vermylen J. A higher than expected incidence of factor VIII inhibitors in multitransfused haemophilia A patients treated with an intermediate purity pasteurized factor VIII concentrate. Thromb Haemost 1993; 69: 115-8.
4. Peerlinck K, Arnout J, Di Giambattista M, Gilles JG, Laub R, Jacquemin M, Saint-Remy JM, Vermylen J. Factor VIII inhibitors in previously treated haemophilia A patients with a double virus-inactivated plasma derived factor VIII concentrate. Thromb Haemost 1997; 77: 80-6.
5. Nightingale J, Godwin K, Gregory K, Winter M. Does continuous infusion of factor VIII predispose to inhibitor development? Haemophilia 1998; 4: 183A.
6. Van den Berg HM, Roosendaal G, Voorberg J, Mauser-Bunschoten EP. Inhibitor development in a multitransfused patient with severe haemo philia A. Thromb Haemost 1999; 82: 151-2.
7. Bleak S, Rodgers GM. Appearance of an inhibitor to factor VIII in a hemophilia A patient with HIV infection treated with combination anti-retroviral therapy. Am J Hematol 1998; 58: 155.
8. Castenskiold EC, Colvin BT, Kelsey SM. Acquired factor VIII inhibitor associated with chronic interferon-alpha therapy in a patient with hae mophilia A. Br J Haematol 1994; 87: 434-6.
9. Lusher JM, Lee CA, Kessler CM, Bedrosian CL. ReFacto Phase 3 Study Group. The safety and efficacy of B-domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A. Haemophilia 2003; 9: 38-19.